HK1255815A1 - 治療腹膜癌的組合物和方法 - Google Patents
治療腹膜癌的組合物和方法Info
- Publication number
- HK1255815A1 HK1255815A1 HK18114889.5A HK18114889A HK1255815A1 HK 1255815 A1 HK1255815 A1 HK 1255815A1 HK 18114889 A HK18114889 A HK 18114889A HK 1255815 A1 HK1255815 A1 HK 1255815A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compositions
- methods
- peritoneal cancers
- treating peritoneal
- treating
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 201000002628 peritoneum cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562193217P | 2015-07-16 | 2015-07-16 | |
US201662298980P | 2016-02-23 | 2016-02-23 | |
PCT/US2016/042302 WO2017011670A1 (en) | 2015-07-16 | 2016-07-14 | Compositions and methods for treating peritoneal cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1255815A1 true HK1255815A1 (zh) | 2019-08-30 |
Family
ID=57757735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18114889.5A HK1255815A1 (zh) | 2015-07-16 | 2018-11-21 | 治療腹膜癌的組合物和方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US10071118B2 (zh) |
EP (1) | EP3322439A4 (zh) |
JP (1) | JP2018521069A (zh) |
KR (1) | KR20180030879A (zh) |
AU (1) | AU2016294602A1 (zh) |
CA (1) | CA2992122A1 (zh) |
HK (1) | HK1255815A1 (zh) |
TW (1) | TW201716072A (zh) |
WO (1) | WO2017011670A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
CA3060443A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
CN108853144A (zh) * | 2017-05-16 | 2018-11-23 | 科济生物医药(上海)有限公司 | Toll样受体激动剂与免疫效应细胞的联用 |
US10927168B2 (en) | 2017-10-02 | 2021-02-23 | Humanicen, Inc. | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab |
US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
WO2019070680A2 (en) * | 2017-10-02 | 2019-04-11 | Humanigen, Inc. | METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING GM-CSF ANTAGONIST |
US10899831B2 (en) | 2017-10-02 | 2021-01-26 | Humanigen, Inc. | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
TW202110873A (zh) | 2019-04-30 | 2021-03-16 | 美商聖堤生物科技股份有限公司 | 嵌合受體及其使用方法 |
WO2021108648A2 (en) * | 2019-11-26 | 2021-06-03 | Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center | Chimeric receptors to cea and methods of use thereof |
CN111292854A (zh) * | 2020-02-19 | 2020-06-16 | 首都医科大学附属北京世纪坛医院 | 预后预测方法、系统及设备 |
CN111914938B (zh) * | 2020-08-06 | 2024-01-30 | 上海金桥信息股份有限公司 | 一种基于全卷积二分支网络的图像属性分类识别方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070031438A1 (en) * | 2001-12-10 | 2007-02-08 | Junghans Richard P | Antibodies as chimeric effector cell receptors against tumor antigens |
CN103442768A (zh) * | 2011-01-18 | 2013-12-11 | 宾夕法尼亚大学董事会 | 治疗癌的组合物和方法 |
US11369666B2 (en) | 2012-12-17 | 2022-06-28 | Newsouth Innovations Pty Limited | Treatment of diseases involving mucin |
-
2016
- 2016-07-14 KR KR1020187004608A patent/KR20180030879A/ko unknown
- 2016-07-14 CA CA2992122A patent/CA2992122A1/en not_active Abandoned
- 2016-07-14 EP EP16825185.8A patent/EP3322439A4/en not_active Withdrawn
- 2016-07-14 WO PCT/US2016/042302 patent/WO2017011670A1/en unknown
- 2016-07-14 AU AU2016294602A patent/AU2016294602A1/en not_active Abandoned
- 2016-07-14 US US15/210,818 patent/US10071118B2/en not_active Expired - Fee Related
- 2016-07-14 JP JP2018501870A patent/JP2018521069A/ja active Pending
- 2016-07-15 TW TW105122446A patent/TW201716072A/zh unknown
-
2018
- 2018-08-13 US US16/102,194 patent/US20180344769A1/en not_active Abandoned
- 2018-11-21 HK HK18114889.5A patent/HK1255815A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR20180030879A (ko) | 2018-03-26 |
JP2018521069A (ja) | 2018-08-02 |
US20180344769A1 (en) | 2018-12-06 |
TW201716072A (zh) | 2017-05-16 |
US20170014452A1 (en) | 2017-01-19 |
WO2017011670A1 (en) | 2017-01-19 |
CA2992122A1 (en) | 2017-01-19 |
EP3322439A1 (en) | 2018-05-23 |
EP3322439A4 (en) | 2019-03-20 |
AU2016294602A1 (en) | 2018-02-08 |
US10071118B2 (en) | 2018-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL267247B (en) | Compositions and methods for treating cancer | |
IL304820A (en) | Preparations and methods for the treatment of cancer | |
HK1251407A1 (zh) | 治療癌症的方法 | |
IL263224A (en) | Methods and preparations for the treatment of cancer | |
EP3507304C0 (en) | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH DUOCARS | |
IL266053A (en) | Preparations and methods for the treatment of ezh2-mediated cancer | |
PT3377516T (pt) | Composição para o tratamento do cancro | |
HK1255815A1 (zh) | 治療腹膜癌的組合物和方法 | |
SG11201700079VA (en) | Combination therapy compositions and methods for treating cancers | |
LT3200815T (lt) | Būdai ir kompozicijos, skirti vėžio gydymui | |
IL256523A (en) | Compositions and methods for treating cancer | |
IL274837A (en) | Methods and preparations for the treatment of cancer | |
HK1250944A1 (zh) | 用於治療癌症的方法 | |
HK1250942A1 (zh) | 用於治療癌症的方法 | |
SG10202013112YA (en) | Zinc-gamma-pga compositions and methods for treating cancer | |
EP3154544A4 (en) | Compositions and methods for treating cancers | |
HK1250943A1 (zh) | 用於治療癌症的方法 | |
IL255638A (en) | Compositions and methods for treating cancer | |
ZA201703771B (en) | Compositions and methods for treating hyperkalemia | |
ZA201802268B (en) | Methods and compositions for preventing or treating cancer | |
HK1250958A1 (zh) | 用於治療癌症的組合物和方法 | |
EP3177637A4 (en) | Compositions and methods for treating colorectal cancer |